MedPath

Thiotepa

THIOTEPA FOR INJECTION, USP

Approved
Approval ID

6dc898dc-5949-4aa4-83f8-4bd20c29eb93

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 24, 2023

Manufacturers
FDA

Hikma Pharmaceuticals USA Inc.

DUNS: 001230762

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Thiotepa

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0143-9309
Application NumberANDA075547
Product Classification
M
Marketing Category
C73584
G
Generic Name
Thiotepa
Product Specifications
Route of AdministrationINTRACAVITARY, INTRAVENOUS, INTRAVESICAL
Effective DateMay 24, 2023
FDA Product Classification

INGREDIENTS (2)

THIOTEPAActive
Quantity: 15 mg in 1.5 mL
Code: 905Z5W3GKH
Classification: ACTIB
WATERInactive
Code: 059QF0KO0R
Classification: IACT

Drug Labeling Information

DESCRIPTION SECTION

LOINC: 34089-3Updated: 5/24/2023

DESCRIPTION

Thiotepa for Injection, USP is an ethylenimine-type compound. It is supplied as a non-pyrogenic, sterile Iyophilized powder for intravenous, intracavitary or intravesical administration, containing 15 mg of thiotepa. Thiotepa is a synthetic product with antitumor activity. The chemical name for thiotepa is Tris(1-aziridinyl)phosphine sulfide. Thiotepa has the following structural formula:

![Thiotepa for Injection, USP Structural Formula](/dailymed/image.cfm?name=thiotepa-for-injection-usp- novaplus-1.jpg&id=711646)

Thiotepa for Injection, USP Structural Formula

Thiotepa has the molecular formula C6H12N3PS, and a molecular weight of 189.22. When reconstituted with sterile water for injection, the resulting solution has a pH of approximately 5.5 to 7.5. Thiotepa is stable in alkaline medium and unstable in acid medium.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Thiotepa - FDA Drug Approval Details